夏松磊

[摘要] 目的 探讨重组人脑利钠肽（新活素）治疗急性左心衰后其血浆NT-proBNP的变换趋势。 方法 回顾性分析于2011年4月～2013年6月入我院进行治疗的56例急性左心衰患者的临床资料，按治疗方法将其分为观察组和对照组。对照组行常规抗心衰治疗，观察组以此为基础给予新活素治疗，对两组患者的治疗总有效率以及血浆NT-proBNP的变换趋势进行比较。 结果 两组治疗总有效率比较（x2=9.1636，P=0.0025）；观察组血浆NT-proBNP水平比较（t=2.6744，P=0.0099）。在症状缓解时间、平均住院时间方面比较，差异有统计学意义（P＜0.05）。结论 采用重组人脑利钠肽对急性左心衰患者进行治疗可明显改善患者的症状和体征，在症状缓解时间和住院时间方面均优于常规治疗，值得临床借鉴和推广。

[关键词] 急性左心衰；重组人脑利钠肽；NT-proBNP

[中图分类号] R541.6   [文献标识码] A   [文章编号] 2095-0616（2014）11-47-03

Study on the transformation trend of plasma NT-proBNP in patients with acute left heart failure treated by recombinant human brain natriuretic peptide

XIA Songlei

No.6 Department of Internal Medicine, Sixth People's Hospital of Luoyang City, Luoyang 471003,China

[Abstract] Objective To explore the transformation trend of plasma NT-proBNP in patients with acute left heart failure treated by recombinant human brain natriuretic peptide(Xinhuosu). Methods A retrospective analysis was conducted on the clinical data of 56 cases of acute left heart failure treated in our hospital from Apr. 2011 to Jun. 2013. The patients were assigned to the observation group and the control group according to the treatment methods. The control group was given routine heart failure treatment and the observation group was given Xinhuosu treatment on the basis of routine heart failure treatment. The total effective rate and transformation trend of plasma NT-proBNP were compared between the two groups. Results The two groups had different total effective rate(x2=9.1636, P=0.0025) and different plasma NT-proBNP(t=2.6744, P=0.0099). The two groups also had significant difference with regard to the symptom alleviation time and average hospital stay, with statistical significance(P＜0.05). Conclusion Application of recombinant human brain natriuretic peptide for treatment of patients with acute left heart failure can significantly improve the symptoms and signs, with better efficacy than routine treatment with regard to the symptom alleviation time and hospital stay, which is worthy of clinical reference and promotion.

[Key words] Acute left heart failure;Recombinant human brain natriuretic peptide;NT-proBNP

急性左心衰属于急危重症之一，具有发病急、死亡率高的特点。临床发现，急性左心衰发作时患者血浆中的BNP水平会出现代偿性增高现象，对于心脏代偿状态的维持具有积极作用[1]，这意味着重组人脑利钠肽可以有效改善急性心衰竭的症状。此外，有研究证实，在治疗急性左心衰时应用重组人脑利钠肽具有见效快、安全性高的特点[2]，与常规扩血管药物相比具有较大的优势。我院使用重组人脑利钠肽对2011年4月～2013年6月收治的急性左心衰患者进行了治疗，疗效较为突出，现将具体情况报道如下。

1 资料与方法

1.1 一般资料

本次研究选取我院2011年4月～2013年6月收治的56急性左心衰患者作为研究对象，参照纽约心脏病协会确定的心功能分级标准将上述患者分为Ⅲ～Ⅳ，按治疗方法将患者分为观察组和对照组两组，每组均有28例。……